VOLL MARK 4

What Happened
Mark Voll, Chief Financial Officer of RenovoRx, received a grant of 12,380 restricted stock units (RSUs) on March 25, 2026. The award was reported at a $0.00 price (code A — award/grant), meaning no cash was paid by the reporting person at grant. The filing shows this as a grant rather than a purchase or sale.

Key Details

• Transaction date: 2026-03-25; Form 4 filed: 2026-03-27 (filed within the typical 2-business-day window).
• Transaction type/code: Award/Grant (A). Reported price: $0.00; total cash value at grant: $0.
• Amount: 12,380 restricted stock units (RSUs).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The grant was for Mark Voll’s service as a consultant to the company for January 2026.
• No indication in this filing of a 10% owner status or a sale/purchase tied to a 10b5-1 plan.

Context
RSUs are equity awards that typically vest over time and convert to common shares upon vesting; a $0 grant price is normal for RSU awards and does not reflect future value or liquidity. Because this was an award (not a sale), it does not signal an immediate cashing-out event. Footnote disclosure clarifies the grant was compensation for consulting services (January 2026). As with all insider filings, this is factual reporting of compensation-related equity granted and should not be taken alone as an endorsement or negative signal about the company’s stock.